PIPELINE WATCH - Four Launches, Two Approvals And Six Orphan Drug Designations
This article was originally published in Scrip
Executive Summary
The table records clinical and regulatory developments using data from BioMedTracker. It lists all drugs for which an event was recorded from April 15 to April 21, 2016, divided by event type.
You may also be interested in...
Deal Watch: Pfizer Offloads Troubled ADHD Products To Manufacturer Tris
Tris acquires Pfizer subsidiary Nextwave, which developed pair of ADHD drugs using Tris delivery technology. Lilly gets oral CGRP candidate from Chugai, while Dova signs US co-promotion partner for Doptelet.
Deal Watch: DelMar Takes On Unmet Need In Brain Cancer With Accurexa
Getting ready to take VAL-083 into Phase III in recurrent glioblastoma, DelMar also is partnering with Accurexa to develop an implantable wafer therapeutic combining the drug with other brain cancer chemotherapies. GW Pharmaceuticals sees a surge in its share price as speculation mounts about a possible takeout.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.